The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Open accessAbstract
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [13]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults
Gregg, E. W. (2005) · JAMA · doi:10.1001/jama.293.15.1868 · Cited by 959
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Flagged first, then by citations
Research works printed but not linked: 3
- 1996, Can J Cardiol, 12, 127
- 1994, Lancet, 344, 1383
- Lyznicki JM, 2001, Am Fam Physician, 63, 2185
Cited by
Sorted by citations
Items 901–943 of 943
Lowe, M. R., Butryn, M. L., & Ely, A. V. (2013) · Wiley eBooks · doi:10.1002/9781394260454.ch7
Koch, E., & Plassmann, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00021-9
THE EFFICACY AND SAFETY OF SAXENDA INJECTION FOR WEIGHT LOSS
Alqahtani, M. S. M., ALAsiri, M. H. J., Shaqayan, F. A. A. A., hadadi, W. A. M., Altamimi, S. A. F., & Alodayni, G. S. M. (2022) · European Chemical Bulletin · doi:10.53555/ecb/2022.11.11.149
Riscos e efeitos adversos de suplementos alimentares e medicamentos utilizados para perda de peso
Moreira, E. V. F., & Nogueira, F. C. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n1-528
b. Part II: Early Vascular Aging and Obesity Treatment
Jordan, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00037-4
Recent Progression of Incretin-Based Obesity Treatment
Choi, D. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.2.78
Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_13
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004
Pharmacological Approaches to the Treatment of Obesity
Bray, G. A. (2012) · Wiley eBooks · doi:10.1002/9781394323142.ch18
Introduction to Obesity and Anti-obesity Medications
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_1
Domoto, T., Kozu, H., Kobayashi, I., & Ichikawa, S. (2025) · Japan Journal of Food Engineering · doi:10.11301/jsfe.24659
ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function
Iacovoni, A., Navazio, A., Luca, L. D., Gori, M., Corda, M., Milli, M., Iacoviello, M., Lenarda, A. D., Tano, G. D., Marini, M., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf070
Appel, L., Risinger, R. C., Wall, A. E., Murck, H., Liu, S., Antoni, G., & Lane, R. M. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06861-4
Sex Differences in Cardiovascular-Related Responses to Obesity Treatment
Silver, N., Ghanta, A., Abene, J., Pinto, Y., & Chao, A. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00774-9
Li, K. (2014) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27340191
Evaluation and Treatment of Obesity in Primary Care
Tsai, A. G., Carvajal, R., Hong, P. S., Baxley, A. D., & Wadden, T. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1203-2_19
Jayawardena, R., Francis, T. V., Abhayaratna, S., & Ranasinghe, P. (2021) · Figshare · doi:10.6084/m9.figshare.16986507
Jayawardena, R., Francis, T. V., Abhayaratna, S., & Ranasinghe, P. (2021) · Figshare · doi:10.6084/m9.figshare.16986504
New Updates in Adipocytes and Adipose Tissue
Kristóf, E., & Csősz, É. (2026) · Life · doi:10.3390/life16020300
Gumenyuk, S., Ogirala, A., Szabo, S. T., Koblan, K. S., Hopkins, S. C., & Ufer, M. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01525-3
Inflammation du tissu adipeux au cours de l'obésité humaine : implication des lymphocytes Th17
Caër, C. (2016) · theses.fr (ABES) · doi:10.70675/65eca5dczaa63z4e9az82dbzb223bfe8ef82 · Cited by 1
Pineda-Wieselberg, R. J., Soares, A. H., Napoli, T. F., Scalissi, N. M., & Salles, J. E. N. (2026) · Nutrients · doi:10.3390/nu18091419
Yen, Y., Liao, J.-Y., Lin, T., Wang, Y.-T., Ho, W.-H., & Chen, C.-F. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.118270
Iwan, M., Roncaglioni, A., & Grisoni, F. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00418
Anti-obesity medications impacting the eye: An emerging concern - a narrative review
Khullar, S., Morya, A. K., Aggarwal, S., Singh, A., Sisodiya, P., & Morya, R. (2026) · World Journal of Methodology · doi:10.5662/wjm.118520
Long-term effects of weight-reducing drugs in people with hypertension
Spary-Kainz, U., Posch, N. A. S., Radl-Karimi, C., Jeitler, K., Krenn, C., Siebenhofer, A., Berghold, A., Horvath, K., Winterholer, S., & Semlitsch, T. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub6
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
Xuan, N. T. T., Nhi, L. T. T., Mẫn, N. Q., Ly, V. T. K., Phong, L. T. H., Phong, N. H., Liệu, P. K., Sơn, L. L., & Khieu, D. Q. (2026) · Journal of Electrochemical Science and Engineering · doi:10.5599/jese.3318
Obesity and obstructive sleep apnea: from pathophysiology to current clinical approaches
Treptow, E. C., Carneiro, G., Andersen, M. L., Drager, L. F., & Genta, P. R. (2026) · Respiratory Research & Clinical Practice · doi:10.36416/1806-3756/e20250314
Obesity and cardiovascular disease: Mechanistic insights and multimodal management strategies
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100729
Promsuwan, K., Saichanapan, J., Saisahas, K., Soleh, A., Samoson, K., & Limbut, W. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.119311
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Almahmeed, W. A., Barajas-Gamboa, J. S., Zubaid, M., Al‐Ozairi, E., Shehab, A., Al‐Rasadi, K., Khalil, C. A., Busaidi, N. A., Sindi, F. A., Awan, Z. A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70204
Andrade, I., Marra, M. C., da Rocha, R. G., Di-Oliveira, M., Barbedi, E. B., Nascentes, C. C., Richter, E. M., & Muñoz, R. A. A. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.119549
Alam, A., Mahajan, K., Dutta, D., & Kamrul-Hasan, A. B. M. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103673
Ghosh, S., Rakshit, I., & Bhattacharjee, P. (2026) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2026.2741932
The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
Halpern, B., Baur, L. A., Blüher, M., Jackson-Morris, A. M., Ralston, J., & Ryan, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00234-2
FAIRsharing record for: WITHDRAWN: A Resource for Withdrawn and Discontinued Drugs
FAIRsharing Team (2018) · FAIRsharing.org · doi:10.25504/fairsharing.otyqfw
Efeitos do tratamento com sibutramina sobre a qualidade espermática de ratos machos Wistar
Borges, C. D. S. (2013) · Aleph UCLA Undergraduate Research Journal for the Humanities and Social Sciences
Tang, B., Zhang, Y., Wang, Y., Wang, X., An, Z., & Yu, X. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.05.007 · Cited by 31
Metadata
- Authors
- James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- The University of Sydney (AU)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- University College London (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Gentofte Hospital (DK)
- University of Alberta (CA)
- Abbott (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 905-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119779723
- Cited by
- 943
- References
- 33
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 50 · 2023: 40 · 2022: 35 · 2021: 50 · 2020: 45 · 2019: 36 · 2018: 54 · 2017: 38 · 2016: 63 · 2015: 69 · 2014: 75 · 2013: 91 · 2012: 93
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Cambridge
- Eisai
- Novo Nordisk
- Shionogi
- Servier
- Allergan
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sibutramine, cardiovascular outcomes, obesity, overweight, weight management, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, type 2 diabetes, blood pressure, weight loss, older adults, drug safety, appetite suppressants, anti-obesity drugs, cardiovascular events, cardiovascular risk reduction, cardiovascular risk stratification
- MeSH terms
- Aged, Appetite Depressants, Blood Pressure, Cardiovascular Diseases, Cyclobutanes, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Obesity, Stroke, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
